Get the Stockscreener App
74.04
2.40%
-1.82
After Hours:
74.04
Haemonetics Corp stock is traded at $74.04, with a volume of 616.42K.
It is down -2.40% in the last 24 hours and down -0.76% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$75.86
Open:
$74.88
24h Volume:
616.42K
Relative Volume:
1.13
Market Cap:
$3.56B
Revenue:
$1.36B
Net Income/Loss:
$123.81M
P/E Ratio:
30.72
EPS:
2.41
Net Cash Flow:
$20.35M
1W Performance:
-0.30%
1M Performance:
-0.76%
6M Performance:
+7.23%
1Y Performance:
-17.78%
1-Day Range:
$73.94
$75.65
1-Week Range:
$73.82
$76.67
52-Week Range:
$55.30
$94.98
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
74.04 | 3.64B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ABT
Abbott Laboratories
|
126.19 | 223.66B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
104.92 | 157.95B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
392.73 | 153.02B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
90.24 | 117.42B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
79.31 | 47.61B | 5.69B | 4.15B | 623.10M | 6.95 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
What makes Haemonetics Corporation stock attractive to long term investorsPattern Recognition Based Market Move Prediction - Newser
What to expect from Haemonetics Corporation in the next 30 daysReal Time Growth Signal with Smart Setup - Newser
Will Haemonetics Corporation see short term momentumFast Entry Strategy with Price Prediction - Newser
Haemonetics Corporation Stock Poised for Technical ComebackBeginner Friendly Stock Selection Guide Updated - metal.it
Is Haemonetics Corporation reversing from oversold territoryControlled Entry Strategy With Safety Analytics - Newser
What makes Haemonetics Corporation stock price move sharplyAI Pattern Recognition and Trade Prediction - Newser
Why Haemonetics Corporation is moving todayRisk Adjusted Trade Signal Screening Tool - Newser
Should you hold or exit Haemonetics Corporation now Smart Safety Strategy With Real Data Analysis - Newser
Does Haemonetics Corporation stock perform well during market downturnsAccelerated profit realization - jammulinksnews.com
Why Haemonetics Corporation stock attracts strong analyst attentionDaily Trade Opportunity - metal.it
Is it the right time to buy Haemonetics Corporation stockDynamic growth stocks - jammulinksnews.com
Haemonetics Builds Momentum with New Buy Rating and Growth Promise - Insider Monkey
Envestnet Asset Management Inc. Has $3.54 Million Stake in Haemonetics Corporation (NYSE:HAE) - Defense World
Haemonetics Holds Successful Annual Shareholders Meeting - The Globe and Mail
What analysts say about Haemonetics Corporation stockConsistently high yield - Autocar Professional
Haemonetics Corporation Stock Analysis and ForecastFree Capital Allocation Plans - jammulinksnews.com
What drives Haemonetics Corporation stock priceTriple-digit return opportunities - jammulinksnews.com
Mutual of America Capital Management LLC Has $1.64 Million Stock Holdings in Haemonetics Corporation (NYSE:HAE) - Defense World
Is Haemonetics Corporation a good long term investmentHigh-margin investment plays - jammulinksnews.com
M&T Bank Corp Acquires Shares of 3,812 Haemonetics Corporation (NYSE:HAE) - Defense World
Nisa Investment Advisors LLC Has $50,000 Position in Haemonetics Corporation (NYSE:HAE) - Defense World
Is Haemonetics Corporation stock a growth or value playMulti Bagger Alerts - Newser
How Haemonetics Corporation stock performs during market volatilityHigh Win Rate Stock Ideas - Newser
Therapeutic Plasma Exchange Market Size, Growth Insights - openPR.com
Platelet Aggregation Devices Market Set to Witness Significant - openPR.com
Lantheus, ICU Medical, Haemonetics, CONMED, and Astrana Health Shares Plummet, What You Need To Know - Yahoo Finance
Haemonetics Announces Q1 FY26 Earnings Release and Conference Call - AInvest
Haemonetics Shares Rise After Upgrade From Citigroup - MarketScreener
Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes - Investing.com
Citigroup Upgrades Haemonetics to Buy From Neutral, Lifts Price Target to $90 From $71 - MarketScreener
New York State Teachers Retirement System Sells 7,800 Shares of Haemonetics Corporation (NYSE:HAE) - Defense World
5 Must-Read Analyst Questions From Haemonetics’s Q1 Earnings Call - Yahoo Finance
Analyst Baird Initiates Coverage on Haemonetics (HAE) with Outperform Rating | HAE Stock News - GuruFocus
Analyst Expectations For Haemonetics's Future - Benzinga
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):